Abstract
Background: Vascular calcification, causing cardiovascular morbidity and mortality, is associated with hyperphosphatemia in chronic kidney disease (CKD). In vitro, phosphate induces transdifferentiation of vascular smooth muscle cells to osteoblast-like cells that express alkaline phosphatase (ALP). In vivo, raised serum ALP activities are associated with increased mortality. A new bone ALP isoform (B1x) has been identified in serum from CKD patients. The present study investigated the different ALP isoforms in calcifying human aortic smooth muscle cells (HAoSMCs). Methods: HAoSMCs were cultured for 30 days in medium containing 5 or 10 mmol/l β-glycerophosphate in the presence or absence of the ALP-specific inhibitor tetramisole. Results: All known bone-specific ALP (BALP) isoforms (B/I, B1x, B1 and B2) were identified in HAoSMCs. β-Glycerophosphate stimulated calcification of HAoSMCs, which was associated with increased BALP isoforms B/I, B1x and B2. Tetramisole inhibited the β-glycerophosphate-induced HAoSMC calcification, which was paralleled by the inhibition of the B1x and B/I, but not the other isoforms. Conclusions: HAoSMCs express the four known BALP isoforms. B/I, B1x and B2 could be essential for soft tissue calcification. B/I and B1x were more affected by tetramisole than the other isoforms, which suggests different biological functions during calcification of HAoSMCs.
References
1.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305.
2.
Moe SM, Drüeke T, Lameire N, Eknoyan G: Chronic kidney disease-mineral-bone disorder: A new paradigm. Adv Chronic Kidney Dis 2007;14:3–12.
3.
Koleganova N, Piecha G, Ritz E, Schirmacher P, Müller A, Meyer HP, Gross ML: Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant 2009;24:2488–2496.
4.
Mizobuchi M, Towler D, Slatopolsky E: Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009;20:1453–1464.
5.
Nikolov IG, Joki N, Nguyen-Khoa T, Ivanovski O, Phan O, Lacour B, Drueke TB, Massy ZA, Dos Reis LM, Jorgetti V, Lafage-Proust MH: Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein E-deficient mice with chronic renal failure. Bone 2010;47:156–163.
6.
Shioi A, Nishizawa Y, Jono S, Koyama H, Hosoi M, Morii H: Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1995;15:2003–2009.
7.
Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10–E17.
8.
Taylor J, Butcher M, Zeadin M, Politano A, Shaughnessy SG: Oxidized low-density lipoprotein promotes osteoblast differentiation in primary cultures of vascular smooth muscle cells by up-regulating osterix expression in an Msx2-dependent manner. J Cell Biochem 2011;112:581–588.
9.
Moe SM, Chen NX: Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008;19:213–216.
10.
Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM: Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008;118:1748–1757.
11.
Yoshida H, Yokoyama K, Yaginuma T, Ohkido I, Yamamoto H, Utsunomiya Y, Kawakami M, Hosoya T: Difference in coronary artery intima and media calcification in autopsied patients with chronic kidney disease. Clin Nephrol 2011;75:1–7.
12.
Drechsler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, Ketteler M, Boeschoten EW, Brandenburg V: Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011;6:1752–1759.
13.
Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CL, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771–780.
14.
Millán JL: Mammalian Alkaline Phosphatase: from Biology to Applications in Medicine and Biotechnology. Weinheim, Wiley, 2006.
15.
Magnusson P, Degerblad M, Sääf M, Larsson L, Thorén M: Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency. J Bone Miner Res 1997;12:210–220.
16.
Fedde KN, Blair L, Silverstein J, Coburn SP, Ryan LM, Weinstein RS, Waymire K, Narisawa S, Millán JL, MacGregor GR, Whyte MP: Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J Bone Miner Res 1999;14:2015–2026.
17.
Anderson HC, Sipe JB, Hessle L, Dhanyamraju R, Atti E, Camacho NP, Millán JL, Dhamyamraju R: Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice. Am J Pathol 2004;164:841–847.
18.
Wennberg C, Hessle L, Lundberg P, Mauro S, Narisawa S, Lerner UH, Millán JL: Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J Bone Miner Res 2000;15:1879–1888.
19.
Johnson KA, Hessle L, Vaingankar S, Wennberg C, Mauro S, Narisawa S, Goding JW, Sano K, Millan JL, Terkeltaub R: Osteoblast tissue-nonspecific alkaline phosphatase antagonizes and regulates PC-1. Am J Physiol Regul Integr Comp Physiol 2000;279:R1365–R1377.
20.
Magnusson P, Löfman O, Larsson L: Determination of alkaline phosphatase isoenzymes in serum by high-performance liquid chromatography with post-column reaction detection. J Chromatogr 1992;576:79–86.
21.
Magnusson P, Häger A, Larsson L: Serum osteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents. Pediatr Res 1995;38:955–961.
22.
Magnusson P, Larsson L, Englund G, Larsson B, Strang P, Selin-Sjögren L: Differences of bone alkaline phosphatase isoforms in metastatic bone disease and discrepant effects of clodronate on different skeletal sites indicated by the location of pain. Clin Chem 1998;44:1621–1628.
23.
Magnusson P, Sharp CA, Farley JR: Different distributions of human bone alkaline phosphatase isoforms in serum and bone tissue extracts. Clin Chim Acta 2002;325:59–70.
24.
Haarhaus M, Fernström A, Magnusson M, Magnusson P: Clinical significance of bone alkaline phosphatase isoforms, including the novel B1x isoform, in mild to moderate chronic kidney disease. Nephrol Dial Transplant 2009;24:3382–3389.
25.
Magnusson P, Sharp CA, Magnusson M, Risteli J, Davie MWJ, Larsson L: Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int 2001;60:257–265.
26.
Magnusson P, Farley JR: Differences in sialic acid residues among bone alkaline phosphatase isoforms: A physical, biochemical, and immunological characterization. Calcif Tissue Int 2002;71:508–518.
27.
Sharp CA, Linder C, Magnusson P: Analysis of human bone alkaline phosphatase isoforms: Comparison of isoelectric focusing and ion-exchange high-performance liquid chromatography. Clin Chim Acta 2007;379:105–112.
28.
Magnusson P, Löfman O, Larsson L: Methodological aspects on separation and reaction conditions of bone and liver alkaline phosphatase isoform analysis by high-performance liquid chromatography. Anal Biochem 1993;211:156–163.
29.
Limas CJ, Cohn JN: Alkaline phosphatase in vascular smooth muscle. Nat New Biol 1973;245:53–55.
30.
Chen NX, O’Neill KD, Duan D, Moe SM: Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002;62:1724–1731.
31.
Shioi A, Katagi M, Okuno Y, Mori K, Jono S, Koyama H, Nishizawa Y: Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-α and oncostatin M derived from macrophages. Circ Res 2002;91:9–16.
32.
Cheung BM, Ong KL, Wong LY: Elevated serum alkaline phosphatase and peripheral arterial disease in the United States National Health and Nutrition Examination Survey 1999–2004. Int J Cardiol 2009;135:156–161.
33.
Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML, Wiebe N, Muntner P: Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009;120:1784–1792.
34.
Beddhu S, Ma X, Baird B, Cheung AK, Greene T: Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1805–1810.
35.
Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K: Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 2010;25:3003–3011.
36.
Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, Van Wyck D, Kopple JD, Kalantar-Zadeh K: Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008;19:2193–2203.
37.
Sigrist MK, Taal MW, Bungay P, McIntyre CW: Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007;2:1241–1248.
38.
Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, Malluche HH: Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 2008;23:1850–1858.
39.
Kozlenkov A, Le Du MH, Cuniasse P, Ny T, Hoylaerts MF, Millán JL: Residues determining the binding specificity of uncompetitive inhibitors to tissue-nonspecific alkaline phosphatase. J Bone Miner Res 2004;19:1862–1872.
40.
Halling Linder C, Narisawa S, Millán JL, Magnusson P: Glycosylation differences contribute to distinct catalytic properties among bone alkaline phosphatase isoforms. Bone 2009;45:987–993.
41.
Olesen P, Nguyen K, Wogensen L, Ledet T, Rasmussen LM: Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Am J Physiol Heart Circ Physiol 2007;292:H1058–H1064.
42.
Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM: Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001;89:1147–1154.
43.
Montes de Oca A, Madueno JA, Martinez-Moreno JM, Guerrero F, Munoz-Castaneda J, Rodriguez-Ortiz ME, Mendoza FJ, Almaden Y, Lopez I, Rodriguez M, Aguilera-Tejero E: High-phosphate-induced calcification is related to SM22α promoter methylation in vascular smooth muscle cells. J Bone Miner Res 2010;25:1996–2005.
44.
Oros M, Zavaczki E, Vadasz C, Jeney V, Tosaki A, Lekli I, Balla G, Nagy L, Balla J: Ethanol increases phosphate-mediated mineralization and osteoblastic transformation of vascular smooth muscle cells. J Cell Mol Med 2012;16:2219–2226.
45.
Prosdocimo DA, Wyler SC, Romani AM, O’Neill WC, Dubyak GR: Regulation of vascular smooth muscle cell calcification by extracellular pyrophosphate homeostasis: synergistic modulation by cyclic AMP and hyperphosphatemia. Am J Physiol Cell Physiol 2010;298:C702–C713.
46.
Sage AP, Lu J, Tintut Y, Demer LL: Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int 2011;79:414–422.
47.
Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, Rees L, Shanahan CM: Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010;21:103–112.
48.
Lomashvili KA, Garg P, Narisawa S, Millán JL, O’Neill WC: Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008;73:1024–1030.
49.
Shan PF, Lu Y, Cui RR, Jiang Y, Yuan LQ, Liao EY: Apelin attenuates the osteoblastic differentiation of vascular smooth muscle cells. PLoS One 2011;6:e17938.
50.
Leroux-Berger M, Queguiner I, Maciel TT, Ho A, Relaix F, Kempf H: Pathologic calcification of adult vascular smooth muscle cells differs on their crest or mesodermal embryonic origin. J Bone Miner Res 2011;26:1543–1553.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
